Tokyo, Aug 7, 2006 (JCN) - Banyu Pharmaceutical Co., Ltd. and Ono Pharmaceutical Co., Ltd. will begin Phase III Clinical Trial of Sitagliptin (Development Code: MK-0431/ONO-5435) in Japan. Sitagliptin is a member of a potentially new class of oral drugs (DPP-4 inhibitors) that enhances the body’s ability to lower blood sugar when it is elevated.
